Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)
Clinical trial NCT05396833 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05396833
- Sponsor
- EMD Serono Research & Development Institute, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-07
- Primary completion
- 2027-01-14
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.